272 related articles for article (PubMed ID: 23298324)
1. Development of meloxicam in situ implant formulation by quality by design principle.
Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
[TBL] [Abstract][Full Text] [Related]
2. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam.
Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T
Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681
[TBL] [Abstract][Full Text] [Related]
3. Response surface methodology to obtain beta-estradiol biodegradable microspheres for long-term therapy of osteoporosis.
Zaghloul AA; Mustafa F; Siddiqui A; Khan M
Pharm Dev Technol; 2006; 11(3):377-87. PubMed ID: 16895848
[TBL] [Abstract][Full Text] [Related]
4. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.
Ahmed TA; Alharby YA; El-Helw AR; Hosny KM; El-Say KM
Drug Des Devel Ther; 2016; 10():405-15. PubMed ID: 26855565
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam.
Khurana S; Jain NK; Bedi PM
Life Sci; 2013 Nov; 93(21):763-72. PubMed ID: 24113071
[TBL] [Abstract][Full Text] [Related]
6. Formulation optimization of transdermal meloxicam potassium-loaded mesomorphic phases containing ethanol, oleic acid and mixture surfactant using the statistical experimental design methodology.
Huang CT; Tsai CH; Tsou HY; Huang YB; Tsai YH; Wu PC
J Microencapsul; 2011; 28(6):508-14. PubMed ID: 21726123
[TBL] [Abstract][Full Text] [Related]
7. A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.
Ahmed TA; Aljaeid BM
Int J Nanomedicine; 2017; 12():1863-1875. PubMed ID: 28331311
[TBL] [Abstract][Full Text] [Related]
8. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
Bachhav YG; Patravale VB
Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
[TBL] [Abstract][Full Text] [Related]
9. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi A; Jamali F
Eur J Pharm Biopharm; 2008 Nov; 70(3):889-94. PubMed ID: 18715548
[TBL] [Abstract][Full Text] [Related]
11. Improved absorption of meloxicam via salt formation with ethanolamines.
Han HK; Choi HK
Eur J Pharm Biopharm; 2007 Jan; 65(1):99-103. PubMed ID: 16919925
[TBL] [Abstract][Full Text] [Related]
12. Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.
Xu H; Zhong H; Liu M; Xu C; Gao Y
Pharmazie; 2011 Sep; 66(9):654-61. PubMed ID: 22026119
[TBL] [Abstract][Full Text] [Related]
13. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
14. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
Shende PK; Gaud RS; Bakal R; Patil D
Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
[TBL] [Abstract][Full Text] [Related]
15. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
16. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization.
Ah YC; Choi JK; Choi YK; Ki HM; Bae JH
Int J Pharm; 2010 Jan; 385(1-2):12-9. PubMed ID: 19833177
[TBL] [Abstract][Full Text] [Related]
17. A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design.
Aboelwafa AA; Fahmy RH
Pharm Dev Technol; 2012; 17(1):1-14. PubMed ID: 20550483
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N
Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284
[TBL] [Abstract][Full Text] [Related]
19. Elastic liposomes bearing meloxicam-beta-cyclodextrin for transdermal delivery.
Jain SK; Gupta Y; Jain A; Amin S
Curr Drug Deliv; 2008 Jul; 5(3):207-14. PubMed ID: 18673264
[TBL] [Abstract][Full Text] [Related]
20. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.
Bartos C; Ambrus R; Sipos P; Budai-Szűcs M; Csányi E; Gáspár R; Márki Á; Seres AB; Sztojkov-Ivanov A; Horváth T; Szabó-Révész P
Int J Pharm; 2015 Aug; 491(1-2):198-207. PubMed ID: 26142244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
